TREATMENT OF ANEMIA IN HEMODIALYSIS-PATIENTS WITH ERYTHROPOIETIN - LONG-TERM EFFECTS ON EXERCISE CAPACITY

被引:0
|
作者
BARANY, P [1 ]
FREYSCHUSS, U [1 ]
PETTERSSON, E [1 ]
BERGSTROM, J [1 ]
机构
[1] HUDDINGE UNIV HOSP, DEPT CLIN PHYSIOL, S-14186 HUDDINGE, SWEDEN
关键词
ANEMIA; ERYTHROPOIETIN; EXERCISE; HEMODIALYSIS; UREMIA;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
1. The effects of correcting anaemia on exercise capacity were evaluated in 21 haemodialysis patients (aged 39 +/- 12 years) before starting treatment with recombinant human erythropoietin (Hb concentration, 73 +/- 10 g/l; total Hb, 59 +/- 12% of expected), after correction of the anaemia to a Hb concentration of 108 +/- 7 g/l and a total Hb 82 +/- 10% of expected, and in 13 of the patients after 12 months on maintenance recombinant human erythropoietin treatment (Hb concentration 104 +/- 14 g/l, total Hb 79 +/- 17% of expected). Fifteen healthy subjects (aged 41 +/- 9 years), who took no regular exercise, constituted the control group. Maximal exercise capacity was determined on a bicycle ergometer. Oxygen uptake, respiratory quotient, blood lactate concentration, heart rate and blood pressure were measured at rest and at maximal workload. 2. After 6 +/- 3 months on recombinant human erythropoietin, maximal exercise capacity increased from 108 +/- 27 W to 130 +/- 36 W (P<0.001) and the maximal oxygen uptake increased from 1.24 +/- 0.39 litres/min to 1.50 +/- 0.45 litres/min (P<0.001). No significant changes in respiratory quotient (1.16 +/- 0.13 versus 1.18 +/- 0.13) and blood lactate concentration (4.0 +/- 1.8 versus 3.6 +/- 1.1 mmol/1) at maximal workload were observed, but the blood lactate concentration in the patients was significantly lower than that in the control subjects (6.7 +/- 2.3 mmol/l, P<0.01). After the correction of anaemia, the aerobic power was still 38% lower in the patients than in the control subjects and 17% lower than the reference values. 3. After 12 months on maintenance recombinant human erythropoietin treatment (17 +/- 3 months from the start of the study), no further significant changes were observed in maximal exercise capacity (before start, 112 +/- 31 W, 6 +/- 3 months, 134 +/- 42 W, 17 +/- 3 months, 134 +/- 50 W), maximal oxygen uptake (before start, 1.33 +/- 0.45 litres/min; 6 +/- 3 months, 1.59 +/- 0.54 litres/min; 17 +/- 3 months, 1.75 +/- 0.78 litres/min) or blood lactate concentration (before start, 4.4 +/- 1.9 mmol/l; 6 +/- 3 months, 4.0 +/- 1.0 mmol/l; 17 +/- 3 months, 4.7 +/- 2.0 mmol/l). 4. Thus, in haemodialysis patients the improvement in maximal aerobic power after the correction of anaemia persists without marked changes during long-term treatment with recombinant human erythropoietin. We did not observe any effects on exercise capacity that could be attributed to a spontaneous increase in physical activity after treatment of anaemia.
引用
收藏
页码:441 / 447
页数:7
相关论文
共 50 条
  • [1] LONG-TERM ERYTHROPOIETIN THERAPY FOR ANEMIA IN HEMODIALYSIS-PATIENTS
    MUIRHEAD, N
    WONG, C
    KIDNEY INTERNATIONAL, 1990, 37 (01) : 312 - 312
  • [2] LONG-TERM EFFECTS ON QUALITY-OF-LIFE IN HEMODIALYSIS-PATIENTS OF CORRECTION OF ANEMIA WITH ERYTHROPOIETIN
    BARANY, P
    PETTERSSON, E
    KONARSKISVENSSON, JK
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1993, 8 (05) : 426 - 432
  • [3] EXERCISE CAPACITY IN HEMODIALYSIS-PATIENTS UNDER LONG-TERM TREATMENT WITH RECOMBINANT HUMAN ERYTHROPOIETIN (R-HUEPO)
    MAYER, G
    CADA, EM
    BARNAS, U
    LUDVIK, G
    GRAF, H
    CLINICAL RESEARCH, 1989, 37 (01): : A148 - A148
  • [4] TREATMENT OF ANEMIA IN HEMODIALYSIS-PATIENTS WITH RECOMBINANT ERYTHROPOIETIN
    WINEARLS, CG
    NEPHRON, 1989, 51 : 26 - 28
  • [5] LONG-TERM EFFECTS OF PARTIAL CORRECTION OF RENAL ANEMIA BY TREATMENT WITH RECOMBINANT HUMAN ERYTHROPOIETIN ON AEROBIC AND ANAEROBIC EXERCISE CAPACITY IN PATIENTS ON CHRONIC-HEMODIALYSIS
    MAYER, G
    THUM, J
    CADA, EM
    STUMMVOLL, HK
    GRAF, H
    NEPHRON, 1989, 51 : 34 - 38
  • [6] TREATMENT OF THE ANEMIA OF HEMODIALYSIS-PATIENTS WITH RECOMBINANT HUMAN ERYTHROPOIETIN
    SCHAEFER, RM
    KUERNER, B
    ZECH, M
    DENNINGER, G
    BORNEFF, C
    HEIDLAND, A
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1988, 11 (04): : 249 - 254
  • [7] EFFECT OF TREATMENT OF ANEMIA WITH ERYTHROPOIETIN ON NEUROMUSCULAR FUNCTION IN PATIENTS ON LONG-TERM HEMODIALYSIS
    SOBH, MA
    ELTANTAWY, AEH
    SAID, E
    ATTA, MG
    REFAIE, A
    NAGATI, M
    GHONEIM, M
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1992, 26 (01): : 65 - 69
  • [8] RECOMBINANT ERYTHROPOIETIN IMPROVES EXERCISE CAPACITY IN ANEMIC HEMODIALYSIS-PATIENTS
    ROBERTSON, HT
    HALEY, NR
    GUTHRIE, M
    CARDENAS, D
    ESCHBACH, JW
    ADAMSON, JW
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1990, 15 (04) : 325 - 332
  • [9] EFFECTS OF ERYTHROPOIETIN TREATMENT ON THYROID-DYSFUNCTION IN HEMODIALYSIS-PATIENTS WITH RENAL ANEMIA
    TOMODA, F
    TAKADA, M
    IZUMINO, K
    OHHASHI, S
    UENO, H
    IIDA, H
    NEPHRON, 1994, 66 (03) : 307 - 311
  • [10] WORSENING OF ANEMIA INDUCED BY LONG-TERM USE OF CAPTOPRIL IN HEMODIALYSIS-PATIENTS
    HIRAKATA, H
    ONOYAMA, K
    ISEKI, K
    KUMAGAI, H
    FUJIMI, S
    OMAE, T
    AMERICAN JOURNAL OF NEPHROLOGY, 1984, 4 (06) : 355 - 360